trending Market Intelligence /marketintelligence/en/news-insights/trending/asBS-6pmT_9FAXfgkzwc0A2 content esgSubNav
In This List

Merck's Keytruda fails to improve survival in triple-negative breast cancer

Blog

Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022


Merck's Keytruda fails to improve survival in triple-negative breast cancer

Merck & Co. Inc.'s blockbuster immuno-oncology drug Keytruda failed to meet its main goal of improving survival in certain breast cancer patients compared to chemotherapy in a late-stage study.

The study, named Keynote-119, evaluated the anti-PD1 therapy alone in metastatic triple-negative breast cancer after patients had already received prior treatments that did not show benefit.

Secondary goals were not tested because the primary goal was not met, the Kenilworth, N.J.-based company stated in a May 20 press release.

Merck will report the results of the trial at an upcoming medical meeting.

Keytruda, also known as a checkpoint inhibitor that activates T-cells in the body, is approved for multiple cancer indications and is being tested in over 900 clinical trials.

SNL Image